Richard Francis Sells 442,935 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) CEO Richard Francis sold 442,935 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total transaction of $14,333,376.60. Following the transaction, the chief executive officer directly owned 642,099 shares of the company’s stock, valued at $20,778,323.64. This represents a 40.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Teva Pharmaceutical Industries Stock Performance

TEVA traded down $1.19 on Thursday, hitting $31.72. 9,925,965 shares of the stock traded hands, compared to its average volume of 9,707,048. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $37.35. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. The firm has a market capitalization of $36.47 billion, a PE ratio of 26.43, a P/E/G ratio of 10.80 and a beta of 0.72. The business has a fifty day moving average price of $33.03 and a two-hundred day moving average price of $26.07.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter last year, the company earned $0.71 EPS. The company’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Large investors have recently modified their holdings of the stock. Dorsey Wright & Associates bought a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at about $1,640,000. Compound Planning Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $323,000. Invesco Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 4.8% in the 4th quarter. Invesco Ltd. now owns 2,710,105 shares of the company’s stock valued at $84,582,000 after acquiring an additional 124,304 shares during the last quarter. Corient Private Wealth LLC raised its position in shares of Teva Pharmaceutical Industries by 30.4% in the 4th quarter. Corient Private Wealth LLC now owns 49,848 shares of the company’s stock valued at $1,520,000 after acquiring an additional 11,628 shares during the period. Finally, Alpine Woods Capital Investors LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $463,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. The Goldman Sachs Group increased their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Jefferies Financial Group lifted their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Finally, Scotiabank upped their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Blackstone Life Sciences agreed to provide $400M to advance Teva’s duvakitug (a Phase 3 antibody for ulcerative colitis/Crohn’s). The deal brings non-dilutive capital, de-risks development funding and validates Teva’s pivot toward innovative specialty assets. Teva and Blackstone Life Sciences Announce $400M Strategic Growth Capital Agreement
• Positive Sentiment: Piper Sandler reaffirmed an “overweight” rating and nudged its price target to $41 (from $40), signaling analyst confidence in TEVA’s upside vs. peers. That supports longer-term investor interest despite near-term volatility. Piper Sandler Overweight Rating
• Neutral Sentiment: Sector coverage notes ongoing pricing pressure in generics; Teva is highlighted as pursuing complex generics and biosimilars to offset headwinds — strategy may protect growth but execution risk remains. 3 Generic Drug Stocks to Watch
• Neutral Sentiment: Broader industry coverage on AI adoption in pharma could benefit larger, R&D-focused players over time; not an immediate stock driver but relevant to Teva’s innovation push. Pharma Industry’s AI Adoption
• Negative Sentiment: CEO Richard Francis sold 442,935 shares (~41% reduction of his position) at ~$32.36 per share, a large insider disposition that can spook investors even if for personal/portfolio reasons. SEC filing: SEC Filing – Insider Sale
• Negative Sentiment: Notable investor exits: billionaire Stanley Druckenmiller trimmed Teva in recent 13F activity, indicating some large-manager profit-taking or rotation away from the name. Druckenmiller Trimmed Teva
• Negative Sentiment: Opinion pieces suggest income-focused investors may prefer higher-yield competitors, which could siphon dividend-oriented demand from TEVA in the near term. Dividend Comparison Article

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.